ICICI Securities's research report on PCBL
PCBL’s Q1FY25 volume growth accelerated with new capacity addition alongside spreads remaining favourable. The company expects volumes to grow at a CAGR of 11–12% p.a. over the next five years; and plans for large capex to capture the opportunity. It also anticipates EBITDA/kg to enhance by INR 4-5/kg in 4–5 years on better product mix and efficiency gains. Aquapharm also plans to grow revenue by 15–20% p.a. over the next few years, as it expands market share in phosphonates in conjunction with a sharp rise in capacities in green chelates and other products. PCBL expects to increase net profit to INR 25bn (5x) in next five years; which is ambitious, in our view.
Outlook
We cut our FY25E EPS by 1.5%, but raise FY26E EPS by 19%, factoring in management optimism. Our target price is increased to INR 375 (from INR 290), as we raise FY26E PE multiple to 20x (from 18x). Downgrade to HOLD (from Buy).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.